QUANTUM GENOMICS (Germany) Performance
| 2QG Stock | EUR 0.07 0.00 0.00% |
The company owns a Beta (Systematic Risk) of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and QUANTUM GENOMICS are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days QUANTUM GENOMICS EO has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, QUANTUM GENOMICS is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
1 | European defence stocks selloff deepens on Ukraine peace talks - Reuters | 11/24/2025 |
2 | Cannabis Stocks Surge. Trump May Reclassify Marijuanabut White House Says a Final Decision Hasnt Been Made. - Barrons | 12/12/2025 |
3 | Rare-Earth Stocks Get a Boost From Something New Results - Barrons | 01/21/2026 |
QUANTUM |
QUANTUM GENOMICS Relative Risk vs. Return Landscape
If you would invest 6.80 in QUANTUM GENOMICS EO on November 9, 2025 and sell it today you would earn a total of 0.00 from holding QUANTUM GENOMICS EO or generate 0.0% return on investment over 90 days. QUANTUM GENOMICS EO is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded stocks are less volatile than QUANTUM, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
QUANTUM GENOMICS Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of QUANTUM GENOMICS for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for QUANTUM GENOMICS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| QUANTUM GENOMICS generated a negative expected return over the last 90 days | |
| QUANTUM GENOMICS has some characteristics of a very speculative penny stock | |
| QUANTUM GENOMICS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 10. Net Loss for the year was (11.54 M) with loss before overhead, payroll, taxes, and interest of (1.15 M). | |
| QUANTUM GENOMICS EO has accumulated about 27.15 M in cash with (11.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Rare-Earth Stocks Get a Boost From Something New Results - Barrons |
QUANTUM GENOMICS Fundamentals Growth
QUANTUM Stock prices reflect investors' perceptions of the future prospects and financial health of QUANTUM GENOMICS, and QUANTUM GENOMICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on QUANTUM Stock performance.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 6.7 M | ||||
| Shares Outstanding | 69.71 M | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 451,017 X | ||||
| Revenue | 10 | ||||
| EBITDA | (1.47 M) | ||||
| Cash And Equivalents | 27.15 M | ||||
| Cash Per Share | 1.01 X | ||||
| Total Debt | 1.87 K | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (11.96 M) | ||||
| Earnings Per Share | (0.80) X | ||||
About QUANTUM GENOMICS Performance
By analyzing QUANTUM GENOMICS's fundamental ratios, stakeholders can gain valuable insights into QUANTUM GENOMICS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if QUANTUM GENOMICS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if QUANTUM GENOMICS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. The company was founded in 2005 and is based in Paris, France. QUANTUM GENOMICS is traded on Frankfurt Stock Exchange in Germany.Things to note about QUANTUM GENOMICS performance evaluation
Checking the ongoing alerts about QUANTUM GENOMICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for QUANTUM GENOMICS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| QUANTUM GENOMICS generated a negative expected return over the last 90 days | |
| QUANTUM GENOMICS has some characteristics of a very speculative penny stock | |
| QUANTUM GENOMICS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 10. Net Loss for the year was (11.54 M) with loss before overhead, payroll, taxes, and interest of (1.15 M). | |
| QUANTUM GENOMICS EO has accumulated about 27.15 M in cash with (11.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Rare-Earth Stocks Get a Boost From Something New Results - Barrons |
- Analyzing QUANTUM GENOMICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether QUANTUM GENOMICS's stock is overvalued or undervalued compared to its peers.
- Examining QUANTUM GENOMICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating QUANTUM GENOMICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of QUANTUM GENOMICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of QUANTUM GENOMICS's stock. These opinions can provide insight into QUANTUM GENOMICS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for QUANTUM Stock analysis
When running QUANTUM GENOMICS's price analysis, check to measure QUANTUM GENOMICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy QUANTUM GENOMICS is operating at the current time. Most of QUANTUM GENOMICS's value examination focuses on studying past and present price action to predict the probability of QUANTUM GENOMICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move QUANTUM GENOMICS's price. Additionally, you may evaluate how the addition of QUANTUM GENOMICS to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |